Citation Impact
Citing Papers
Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
2007 StandoutNobel
Bispecific antibodies for cancer therapy
2009
Infectious enveloped RNA virus antigenic chimeras.
1992 StandoutNobel
Complex interplay between -catenin signalling and Notch effectors in intestinal tumorigenesis
2011 StandoutNobel
Untangling the ErbB signalling network
2001 Standout
Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
1997
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
2010 Standout
Proteasomal degradation of Atoh1 by aberrant Wnt signaling maintains the undifferentiated state of colon cancer
2008
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
Herceptin: mechanisms of action and resistance
2005
Engineered receptors for soluble cellular communication and disease sensing
2024 StandoutNatureNobel
HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer
1997
Intracellular antibodies and challenges facing their use as therapeutic agents
2003
Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes
1996
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown
2018 StandoutNobel
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
2012 Standout
New approaches to antibody therapy
2000
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
2003 Standout
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands
1998
The ground state of embryonic stem cell self-renewal
2008 StandoutNature
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Antitumour actions of interferons: implications for cancer therapy
2016
Efficacy of small‐molecule glycogen synthase kinase‐3 inhibitors in the postnatal rat model of tau hyperphosphorylation
2007
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Glycans in cancer and inflammation — potential for therapeutics and diagnostics
2005 StandoutNobel
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
2017 StandoutNobel
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Purification and characterisation of a breast-cancer-associated glycoprotein not expressed in normal breast and identified by monoclonal antibody 83D4
1991
GSK3 inhibitors: development and therapeutic potential
2004
Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS
1999
The Ways of Endocytosis
1989
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Macrophages are critical effectors of antibody therapies for cancer
2015
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Distinct Foxp3 enhancer elements coordinate development, maintenance, and function of regulatory T cells
2021 StandoutNobel
Reactive oxygen species have a causal role in multiple forms of insulin resistance
2006 StandoutNature
Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3β on a muscle-specific promoter
2004
Humanized Antibodies as Potential Therapeutic Drugs
1998
AKT/PKB Signaling: Navigating the Network
2017 Standout
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
1997
Glucose Utilization via Glycogen Phosphorylase Sustains Proliferation and Prevents Premature Senescence in Cancer Cells
2012
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Annexin VI is required for budding of clathrin-coated pits
1992 StandoutNobel
Glycogen Synthase Kinase-3 Regulates Mitochondrial Outer Membrane Permeabilization and Apoptosis by Destabilization of MCL-1
2006
Monoclonal antibodies for cancer immunotherapy
2009
Hydroethidine- and MitoSOX-derived red fluorescence is not a reliable indicator of intracellular superoxide formation: Another inconvenient truth
2010
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Aberrant Glycosylation In Tumors And Tumor-Associated Carbohydrate Antigens
1989
Inhibition of Papillomavirus Protein Function in Cervical Cancer Cells by Intrabody Targeting
2005 StandoutNobel
Recombinant Toxins for Cancer Treatment
1991 Science
Ligand-regulated internalization and recycling of human beta 2-adrenergic receptors between the plasma membrane and endosomes containing transferrin receptors.
1992 StandoutNobel
Bond Formations between Two Nucleophiles: Transition Metal Catalyzed Oxidative Cross-Coupling Reactions
2011 Standout
Taking regulatory T cells into medicine
2021 StandoutNobel
Regulatory T Cells and Human Disease
2020 StandoutNobel
Bispecific Antibodies as Novel Bioconjugates
1998
Alternative molecular formats and therapeutic applications for bispecific antibodies
2015
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges
2005
Conversion of antigen-specific effector/memory T cells into Foxp3-expressing T reg cells by inhibition of CDK8/19
2019 StandoutNobel
HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression
2001 StandoutNobel
Antibody-induced receptor loss. Different fates for asialoglycoproteins and the asialoglycoprotein receptor in HepG2 cells.
1986 StandoutNobel
Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3
2004
Cytokine Storm
2020 Standout
Chimeric Antigen Receptor Therapy
2018 Standout
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Growth Factors and Cancer
1991 StandoutScience
Routing of internalized ricin and ricin conjugates to the Golgi complex.
1986
Superoxide Ion: Generation and Chemical Implications
2016 Standout
Regioselective Functionalization of the Imidazole Ring via Transition Metal‐Catalyzed CN and CC Bond Forming Reactions
2010
Epigenetic conversion of conventional T cells into regulatory T cells by CD28 signal deprivation
2020 StandoutNobel
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Immunotoxins
1986
Markedly Different Pathogenicity of Four Immunoglobulin G Isotype-Switch Variants of an Antierythrocyte Autoantibody Is Based on Their Capacity to Interact in Vivo with the Low-Affinity Fcγ Receptor III
2000 StandoutNobel
Multiple event activation of a generic prodrug trigger by antibody catalysis
1999 StandoutNobel
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16).
1998
Stereoselective synthesis of the C-analogue of β-d-glucopyranosyl serine
1997 StandoutNobel
Works of David B. Ring being referenced
Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
1995
Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies.
1985
In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III.
1992
Clinical Development of 2B1, a Bispecific Murine Monoclonal Antibody Targeting c-erbB-2 and FcγRIII
1995
Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fcγ RIII
1996
Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment
1997
Selection of hybrid hybridomas by flow cytometry using a new combination of fluorescent vital stains
1991
Inhibition of Human Immunodeficiency Virus Type 1 Replication in Vitro in Acutely and Persistently Infected Human CD4+ Mononuclear Cells Expressing Murine and Humanized Anti-Human Immunodeficiency Virus Type 1 Tat Single-Chain Variable Fragment Intrabodies
1999
Selective Glycogen Synthase Kinase 3 Inhibitors Potentiate Insulin Activation of Glucose Transport and Utilization In Vitro and In Vivo
2003
Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer.
1989
Elevated levels of a high molecular weight antigen detected by antibody W1 in sera from breast cancer patients.
1986
Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor.
1996
Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.
1993
Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins.
1985
Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats
2003
Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines.
1989